t,, Oxygen free radicals such as superoxide radical and iron-catalyzed hydroxyl radical generated by the superoxide system have been implicated in the genesis of brain edema. Therefore, deferoxamine (DFO), an iron chelator, could potentially be used to treat brain edema. To examine this hypothesis, vasogenic brain edema was produced in 48 cats by a cortical freezing lesion. The animals were separated into three groups: Group 1 comprised 14 cats that received no DFO and were sacrificed at 6 or 24 hours; Group 2 consisted of 12 cats that were treated with DFO (50 mg/kg/ml, intravenously) at 15 minutes before the lesion was made and 60 minutes later and were sacrificed at 6 or 24 hours; and Group 3 included 12 cats that were treated with DFO (50 mg/kg/ml, intravenously) at 15 minutes after the lesion was produced and 60 minutes later and were sacrificed at 6 or 24 hours. The effect of DFO on arterial blood pressure was also studied in the remaining 10 cats.
O
XYGEN free radicals such as superoxide radical and iron-catalyzed hydroxyl radical generated by the superoxide system have been implicated in the pathological processes of ischemia, trauma, and inflammation.l~ Recent studies 13"23 have also shown that oxygen free radicals are involved in the genesis of brain edema. Among oxygen free radicals, the hydroxyl radical is one of the most highly reactive species and is produced from two active oxygen species, superoxide radical and hydrogen peroxide, via the iron-catalyzed Haber-Weiss reaction. The hydroxyl radical reacts at great speed with almost every molecule found in living cells, including deoxyribonucleic acid, proteins, and carbohydrates. It attacks the fatty acid side chains and starts the process of lipid peroxidation) 9 Inasmuch as the brain is especially rich in iron, it is possible that the iron-catalyzed Haber-Weiss reaction is involved in the production of hydroxyl radical.~6 Recent interest in the role of iron in oxygen free radical-mediated tissue injury has grown considerably, and the number of reports about the oxygen free radical biochemistry of ironchelating agents is increasing?,~8 Deferoxamine (DFO), a powerful iron chelator used for the treatment of iron overload in humans, 24 has attracted much attention as an effective drug in reperfusion injury. ~1. 26, 30 The implications of these earlier reports stimulated the postulate that DFO can be used to treat brain edema.
In this experimental study the protective effect of DFO on cold-induced edema in cats was investigated.
Materials and Methods
This study was performed in compliance with the National Institutes of Health "Guide for the Care and Use of Laboratory Animals" and was approved by the Johns Hopkins Medical Institutions Animal Services.
Surgical Procedure
Forty-eight cats of either sex, weighing 2.5 to 3.5 kg each, were anesthetized with intramuscular ketamine hydrochloride (25 mg/kg). Brain edema was produced in a standard fashion. A midline scalp incision and a l-cm craniectomy were made in the right parietal region. A metal probe, 2 mm in diameter and cooled to -50~ with dry ice, was applied to the dura for 1 minute to produce cold injury. The tip of the metal probe was disengaged with a flush of normal saline. The dura was left intact but was covered with a piece of Gelfoam. The skin was then closed with sutures. Animals in the 24-hour study were returned to their cages without special postoperative care.
Deferoxamine Administration
Thirty-eight of the animals were separated into three groups. Group 1 consisted of 14 cats that underwent cold-induced edema and were sacrificed at 6 or 24 hours after the lesion was produced. This group was treated with saline (1 ml/kg, intravenously) infused over 5 to 10 minutes at 15 minutes before the lesion was made and 60 minutes later. Group 2 was composed of 12 cats that were treated with DFO (50 mg/kg/ml, intravenously) infused over 5 to 10 minutes at 15 minutes before the lesion was made and 60 minutes later. These animals were sacrificed at 6 or 24 hours after the lesion. Group 3 comprised 12 cats that were treated with DFO (50 mg/kg/ml, intravenously) infused over 5 to 10 minutes at 15 minutes after the lesion was made and 60 minutes later. They also were sacrificed at 6 or 24 hours after the lesion. Sacrifice was by intravenous injection of a pentobarbital overdose.
Arterial Blood Pressure Measurement
Ten cats of either sex, weighing 2.5 to 3.5 kg each, were studied to determine the effect of DFO on arterial blood pressure. A catheter was inserted into the right femoral artery to continuously monitor blood pressure. Five of the 10 cats received saline (1 ml/kg, intravenously) infused over 5 to 10 minutes at 15 minutes before the lesion was made and 60 minutes later. The other five cats received DFO (50 ml/kg/ml, intravenously) infused over 5 to 10 minutes at 15 minutes before the lesion and 60 minutes later. Arterial blood pressure in both groups was observed for about 2 hours following the lesion.
Determination of Brain Water Content
Brain water content was measured by the specific gravity method. Brain samples, approximately 1 cu m m in size, were excised and placed onto a kerosene/monobromobenzene column. The results were read 5 minutes after placement of the sample onto the column. The columns were calibrated with NaC1 solutions of known specific gravity. The eight sampling areas, including those areas of white matter 3 mm, 5 mm, and 7 m m beneath the lesion cortex that showed the maxim u m increase of water content among all sampling areas, are illustrated in Fig. 1 .
Determination of Blood-Brain Barrier Disruption
Competence of the blood-brain barrier (BBB) was assessed by spread of Evans blue dye with planimetry.' Each animal received an intravenous injection of 2.5 ml/kg of 2.5% Evans blue dye immediately prior to sustaining the cold lesion. lesion. The cross-sectional area of the brain cortex and the white matter was evaluated with planimetry. The exact surface area covered by the dye was calculated in square millimeters. This surface area was taken as representative of the progression of the edema front.
Statistical Analysis
Data are presented as mean values + standard deviations. Student's t-test was used to assess significance, with p < 0.05 considered statistically significant. Table 1 summarizes the arterial blood pressure measurements from animals injected with saline or DFO. Following the first injection of DFO there was a decrease in arterial blood pressure but the pressure returned to normal levels within 30 minutes. With the second injection of DFO a transient and slight decrease in arterial blood pressure occurred. Over the subsequent 2 hours there were no significant differences in the arterial blood pressure between the saline-and DFOtreated cats at any time.
Results
Specific gravity values of brain-sampling areas 5, 6, and 7 (see Fig. 1 ) at 6 hours were higher in the DFOpretreated group (Group 2) than in the untreated group (Group 1) (area 5:1.0409 _+ 0.0050 vs. 1.0332 __+ 0.0022, p < 0.01; area 6:1.0472 _+ 0.0020 vs. 1.0350 _+ 0.0025, p < 0.01; and area 7:1.0480 + 0.0009 vs. 1.0406 + 0.0039, p < 0.01). Specific gravity values of areas 5, 6 , and 7 at 6 hours were higher in the DFO-posttreated group (Group 3) than in the untreated group (Group 1) (area 5:1.0386 + 0.0022 vs. 1.0332 __+ 0.0022, p < 0.01; area 6:1.0475 _+ 0.0011 vs. 1.0350 + 0.0025, p < 0.01; and area 7:1.0485 + 0.0005 vs. 1.0406 + 0.0039, p < 0.01) (Fig. 2) .
At 24 hours, specific gravity values in the DFOpretreated group showed similar results compared to the untreated group, except for area 5 (area 6:1.0382 _+ 0.0036 vs. pos~treated group did not have a significant change in specific gravity values in any area (Fig. 3) .
Areas of Evans blue dye extravasation at 6 hours were significantly reduced in the DFO-pretreated and DFO-posttreated groups relative to the untreated group (p < 0.05). At 24 hours there was significant reduction in the Evans blue-extravasated area in the DFO-pretreated group relative to the untreated group (p < 0.001), but the DFO-posttreated group was unchanged (Fig. 4) .
Discussion
Under normal conditions intraceUular iron is stored in the form of ferritin. 9 Biemond, et al., 4 showed that xanthine oxidase is able to effect the mobilization of iron from ferritin, but that this may be inhibited by superoxide dismutase (SOD). Thomas, et al., 33 also reported that superoxide radical produced by xanthine oxidase is able to release iron from ferritin. The role of iron in oxygen free radical formation and lipid peroxidation is thought to be important. Recent in vivo experiments 22'3~ have demonstrated an increase in brain tissue malondialdehyde and low molecular weight chelated iron in the brain of dogs following prolonged cardiac arrest and in the myocardium of dogs subjected to regional ischemia. WiUmore and Rubin 36 emphasized that extravasation of red blood cells with liberation of iron and heme compounds from hemoglobin following intracerebral hematoma, hemorrhagic infarction, and head trauma with contusion was a critical factor in the initiation of brain injury. They also demonstrated the role of iron in the induction of brain edema and free radical formation; that is, iron injected into rat cortex causes formation of superoxide radicals, brain edema, lipid peroxidation, and cortical necrosis at the injected site. 35 The implications of these reports can provide two conceptually different approaches to a new treatment of brain edema. The first approach is to reduce the superoxide radical with SOD. However, our recent studies 23 showed that SOD did not reduce coldinduced edema, and that intracellular uptake of SOD might be necessary for any effect on brain edema. An alternative method may be required to deliver SOD into the intracellular compartment.
A second approach is to inhibit the iron-catalyzed Haber-Weiss reaction by reducing the availability of iron (ferric iron). The present study investigated the effect of DFO, a powerful iron chelator, on cold-induced edema. The half-life of intravenously injected DFO is believed to be about 60 minutes. 24 The DFO was administered 15 minutes before the lesion was made and 60 minutes later (Group 2) or 15 minutes after the lesion and 60 minutes later (Group 3) so as to include the maximum period of free radical production following the lesion; this protocol was chosen because the blood concentration of DFO after a single dose given intravenously may drop to subtherapeutic levels. Deferoxamine has a remarkable high affinity for ferric iron. In vitro studies 9 have shown that DFO removes iron from hemosiderin and ferritin. Deferoxamine has a low molecular weight and passes freely through the BBB and the cell membrane. Keberle 24 showed that the brain has the highest concentrations of DFO 5 hours after intravenous administration of this drug. Deferoxamine does not obstruct iron bound in normal protein structures, and significant anemia does not occur until after 2 weeks of chronic use. Our recent data 23 and those of Chan, et al., ~2.13 both suggest an important role of intracellularly generated reactive oxygen metabolites in the genesis of brain edema. It is believed that DFO reaches these intracellular sites of free radical generation. Halliwell and Gutteridge ~9 summarized both the potential and the demonstrated effects of DFO on biological systems. Sinaceur, et al. 32 reported that DFO also acts as a direct scavenger of superoxide radical, which is different from SOD with its dismutation effect.
Deferoxamine has been successfully used clinically to treat patients with acute and chronic iron overload syndromes. Recent experimental studies have shown that DFO has an important therapeutic potential in the treatment of postischemic brain injury, lj myocardial injury, 6'28 gentamicin-induced acute renal failure, 34 nephritis, 31 skin flap necrosis, 2 and intestinal ischemia. 21 This drug has been given by the subcutaneous and intravenous routes in increasingly high doses, and some reports of chronic and acute toxicity (development of cataracts, retinal abnormalities, anaphylaxis, visual loss, and audiotoxicity) have appearedfl '14'17 Halliwell and Gutteridge 19 also emphasized that extreme caution must be used when combining DFO and phenothiazine drugs because of neurological side effects. Therefore, DFO is not an ideal iron chelator for the treatment of brain edema, brain trauma, and ischemia. Other iron chelating agents such as 2,3-dihydroxybenzoate or phenanthroline 18 will also have to be evaluated.
The findings of this study lead to two important conclusions. Deferoxamine inhibits the occurrence and early development of brain edema and BBB disruption following cold injury. This study showed that DFO produced transient hypotension following the injection, most likely secondary to the histamine-releasing properties of DFO. 16 Arterial blood pressure returned to normal within 30 minutes. Over the subsequent experimental period there were no significant differences in arterial blood pressure between the saline-treated and DFO-treated cats at any time. Klatzo 25 indicated that elevation of mean arterial blood pressure dramatically accelerates the spread of edema, and the reverse is true when the blood pressure is significantly reduced. Our study also showed that the drug dose and infusion rate we used were found to be well tolerated without significant changes in systolic and diastolic arterial blood pressure. The effectiveness of DFO pretreatment as assessed at 6 or 24 hours and of DFO posttreatment as assessed at 6 hours following injury in this study does not appear to relate to a transient decrease in arterial blood pressure; instead it may be due to the primary action of DFO on oxygen free radicals. Farber, et aL, ~5 reported that there were no significant differences in any hemodynamic parameter such as coronary blood flow, heart rate, and mean arterial blood pressure between saline-and DFO-treated dogs at any time in a myocardial reperfusion model. The failure of the effectiveness of the drug in the DFO-posttreated group at 24 hours following injury requires further study. A second direct inference from the data is that the therapeutic effect of an iron chelator implies a role of iron in the genesis of cold-induced edema.
Little is known about the role of iron in the initiation of lipid peroxidation and free radical formation. The iron-catalyzed Haber-Weiss reaction in the initiation of lipid peroxidation is the most widely proposed mechanism. Minotti and Aust 29 suggested two roles for iron in the initiation of lipid peroxidation: 1) iron serves as a catalyst for the formation of the highly reactive hydroxyl radical, which initiates lipid peroxidation; and 2) iron, perhaps in the form of an oxygen-bridged Fe ++-Fe +++ complex, is the actual initiator of lipid peroxidation. Kornbrust and Mavis 27 and Bucher, et al., 8 have reported that free ferrous iron can act as a direct initiator of membrane peroxidation through a mechanism possibly involving a ferrous iron-oxygen complex, ruling out a role for hydroxyl radicals produced by reduction of H202 by Fe ++. Braughler, et al., 7 suggested that the absolute ratio of Fe +++ to Fe ++ was the primary determining factor for the initiation of lipid peroxidation, and no hydroxyl radical formation could be detected with their experimental system. The precise role and action of iron and the protective effects of an iron chelator on brain edema warrant further study.
